In a single-arm phase II clinical trial, 31 patients with progressive metastatic MTC and with tumor uptake at pre-therapeutic scintigraphy, treatment with radiolabeled octreotide, [90-octrio-DOTA]-TOC, resulted in decreased calcitonin levels in nine patients (29%). The gene discussed is CALCA; the disease is medullary thyroid gland carcinoma.